Serotonin receptor specificity in anxiety disorders

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 6, 1996, Pages 5-10

  Lucki, Irwin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; FLUOXETINE; RECEPTOR SUBTYPE; SEROTONIN 1A AGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ANXIETY NEUROSIS; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; HUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW;

ANXIETY DISORDERS; BUSPIRONE; FLUOXETINE; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0029783673     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Molliver ME. Serotonergic neuronal systems: what their anatomic organization tells us about function. J Clin Psychopharmacol 1987;7(suppl):3-23
2. Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev 1992;72:165-229
3. 1A autoreceptors of the dorsal and median raphe nuclei. J Pharmacol Exp Ther 1994;269:1268-1279
4. Hoyer D, Clarke DE, Fozard JR, et al. VII: International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203
5. Frazer A, Maayani S, Wolfe BB. Subtypes of receptors for serotonin. Ann Rev Pharmacol Toxicol 1990;30:307-348
6. Tye NC, Iversen SD, Green AR. The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology 1979;18:689-695
7. Stein L, Wise CD, Belluzi JD. Effects of benzodiazepines on central serotonergic mechanisms. In: Costa E, Greengard P, eds. Mechanism of Benzodiazepines. New York, NY: Raven Press; 1975:29-44
8. Eison AS, Eison MS. Serotonergic mechanisms in anxiety. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:47-62
9. Handley SL, McBlane JW. 5HT drugs in animal models of anxiety. Psychopharmacology (Berl) 1993;112:13-20
10. Barrett JE, Vanover KE. 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions. Psychopharmacology (Berl) 1993;112:1-12
11. 1 receptors and behavior. Neurosci Biobehav Rev 1992; 16:83-94
12. 1B agonists. Synapse 1987; 1:3-9
13. 1-like and GABA receptors in the dorsal raphe nucleus of the rat. Neuropharmacology 1988;27:993-1001
14. Fuller RW. The involvement of serotonin in regulation of pituitary-adrenocortical function. Front Neuroendocrinol 1992;13:250-270
15. 1A receptors. Biol Psychiatry 1985;20:971-979
16. de Montigny C, Blier P, Chaput Y. Electrophysiologically identified serotonin receptors in the rat CNS. Neuropharmacology 1984;23:1511-1520
17. 1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol 1989;96:283-290
18. 1A selective drugs on the 5-HT behavioral syndrome. Pharmacol Biochem Behav 1986;24:1513-1519
19. 1A receptors and behavioral responses. Neuropsychopharmacology 1990;3:481-493
20. 2 receptor sensitivity after continuous gepirone treatment. Eur J Pharmacol 1985,111:389-392
21. Wieland S, Fischette CT, Lucki I. Effect of chronic treatments with tandospirone and imipramine on serotonin-mediated behavioral responses and monoamine receptors. Neuropharmacology 1993;32:561-573
22. Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 1980;210: 87-89
23. Marek GJ, McDougle CJ, Price LH, et al. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl) 1992;109:2-11
24. 2 receptors. Psychopharmacology (Berl) 1987;93:502-506
25. Gleeson S, Ahlers ST, Mansbach RS, et al. Behavioral studies with anxiolytic drugs, VI: effects on punished responding of drugs interacting with serotonin receptor subtypes. J Pharmacol Exp Ther 1989;250:809-817
26. Ceulemans DLS, Hoppenbrouwers M-LJA, Gelders YG, et al. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind, placebo-controlled study versus lorazepam. Pharmacopsychiatry 1985;18:303-305
27. 1C receptor antagonists. Eur J Pharmacol 1989;164:445-454
28. 2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology (Berl) 1994;114:90-96
29. 2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology (Berl) 1995;188:178-182
30. Lucki I, Ward HR, Frazer A. Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. J Pharmacol Exp Ther 1989;249:155-164
31. 2C/2B receptor function. Neuropharmacology 1994;12:1581-1588
32. Lightowler S, Kennett GA, Williamson IJR, et al. Anxiolytic-like effect of paroxetine in a rat social-interaction test. Pharmacol Biochem Behav 1994; 49:281-285
33. Murphy DL, Mueller EA, Hill JL, et al. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology (Berl) 1989;98:275-282
34. Zohar J, Mueller EA, Insel TR, et al. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry 1987;44:946-951
35. Pigott TA, Zohar J, Hill JL, et al. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry 1991;29: 418-426
36. Seibyl JP, Krystal JH, Price LH, et al. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Res 1991;38:227-236
37. Zohar J, Insel TR, Zohar-Kadouch RC, et al. Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry 1988;45:167-172
38. 3 Antagonists and Benzodiazpines: Their Comparative Behavioural Pharmacology. Chichester, UK: John Wiley; 1991:133-157
39. Blier P, de Montigny C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 1990;51(4, suppl):14-20
40. Kreiss DS, Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 1995;274:866-875
41. Invernizzi R, Belli S, Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 1992;584:322-324
42. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J Neurochem 1993;60:776-779
43. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-251
44. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995; 15:217-222
45. Swanson LW, Hartman BK. The central adrenergic system: an immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-β-hydroxylase as a marker. J Comp Neurol 1975;163:467-506
46. 2-Adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo. Naunyn Schmiedebergs Arch Pharmacol 1992;345:137-143
47. Benloucif S, Keegan MJ, Galloway MP. Serotonin-facilitated dopamine release in vivo: pharmacologic characterization. J Pharmacol Exp Ther 1993; 265:373-377
48. Lucki I, Frazer A. Changes in behavior associated with serotonin receptors following repeated treatment with antidepressant drugs. In: Seiden LS, Balster R, eds. Behavioral Pharmacology: Current Status. New York, NY: Liss; 1985:339-357